Numinus plans a "compassionate access" clinical trial of psilocybin to treat substance abuse.
Numinus plans a "compassionate access" clinical trial of psilocybin to treat substance abuse.
Delic Corp is a Delaware-based psychedelics company that has gone public via RTO.
Field Trip is entering the (already legal) Netherlands psilocybin market with a "Field Trip Health Center" in Amsterdam.
Mydecine provides an update on its Phase 2A clinical trial of psilocybin-assisted psychotherapy for the treatment of PTSD.
Another incremental step forward in one of MindMed's leading psychedelics R&D initiatives.
Mind Cure Health is seeking to raise $3 million via the sale of 6.66 million units.
The Navy SEAL Foundation (NSF) recently pledged one of the organization’s largest single grants in its 20-year history to support a major Post Traumatic Stress Disorder (PTSD) study.
Mind Cure's new Chief Science Officer (CSO) brings experience in drug research as well as natural product development.
Compass joins an international organization dedicated to advancing psychedelic drug research.
Entheon Biomedical has announced that it expects to commence public trading on or about November 12th, symbol "ENBI".
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now